Well Referenced

Tag: melanocortin receptor agonist

The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat

This 2003 preclinical study assessed the neurotrophic and neuroprotective effects of melanotan-II, a potent melanocortin receptor agonist, in a rat model of sciatic nerve injury. Rats received subcutaneous injections of melanotan-II at doses of 2, 20, or 50 μg/kg every 48 hours following a sciatic nerve crush injury. The 20

Read More »
June 26, 2025 No Comments

The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women

This review explores the neurobiological mechanisms of bremelanotide, a melanocortin receptor (MCR) agonist, in treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide activates MC4Rs in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release and enhancing sexual desire. The review discusses how neurotransmitters like norepinephrine and

Read More »
June 26, 2025 No Comments

An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder

Bremelanotide, a melanocortin receptor agonist, has shown statistically significant improvements in sexual desire and reduced distress related to hypoactive sexual desire disorder (HSDD) in premenopausal women. Administered as a subcutaneous injection on an as-needed basis, it provides an on-demand treatment option. However, the overall clinical benefit is modest, and nausea

Read More »
June 26, 2025 No Comments

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

Two phase 3 randomized, double-blind, placebo-controlled trials evaluated the safety and efficacy of bremelanotide, a melanocortin receptor agonist, for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. The trials included 1,267 participants, primarily white and U.S.-based, who received a 1.75 mg subcutaneous injection as needed before sexual activity. Bremelanotide

Read More »
June 26, 2025 No Comments

Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder

Bremelanotide, a melanocortin receptor agonist, has been FDA-approved as an as-needed treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Clinical trials demonstrated statistically significant improvements in sexual desire and reductions in distress related to low libido, though the overall clinical benefit was considered modest. Administered via subcutaneous injection

Read More »
June 26, 2025 No Comments

Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response

This randomized controlled trial investigated the effects of combining low-dose intranasal PT-141 (bremelanotide) with sildenafil in 19 men with erectile dysfunction (ED). The study found that the combination significantly enhanced erectile response during visual sexual stimulation compared to sildenafil alone, without increasing adverse events. PT-141, a melanocortin receptor agonist, acts

Read More »
June 26, 2025 No Comments

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

This randomized controlled trial evaluated the safety, pharmacokinetics, and pharmacodynamics of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction (ED). The study found that PT-141 elicited significant erectile responses at doses greater than 7 mg, with erections occurring approximately 30 minutes post-administration. Pharmacokinetic

Read More »
June 26, 2025 No Comments

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra

This randomized controlled trial evaluated the safety, pharmacokinetics, and pharmacodynamic effects of PT-141, a melanocortin receptor agonist, in both healthy male subjects and patients with erectile dysfunction (ED) who had an inadequate response to sildenafil (Viagra). The study found that doses greater than 1.0 mg in healthy males and doses

Read More »
June 26, 2025 No Comments